GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Treasury Stock

LakeShore Biopharma Co (LakeShore Biopharma Co) Treasury Stock : $0.00 Mil (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. LakeShore Biopharma Co's treasury stock for the quarter that ended in Sep. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


LakeShore Biopharma Co Treasury Stock Historical Data

The historical data trend for LakeShore Biopharma Co's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Treasury Stock Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
Treasury Stock
- - -

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Treasury Stock Get a 7-Day Free Trial - - - - -

LakeShore Biopharma Co Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.